A study to investigate the relative bioavailability and safety of different oral formulations of elecoglipron in healthy participants

Inclusion Criteria

• Inclusion Criteria:
• -Healthy participants with suitable veins for cannulation or repeated venipuncture.
• -All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
• -Females of childbearing potential must not be lactating and if heterosexually active, must agree to use an approved method of highly effective contraception.
• -Females of non-childbearing potential must be confirmed at screening visit as postmenopausal or have documentation of irreversible surgical sterilization.
• -Sexually active fertile male participants with partners of childbearing potential must adhere to the study specific contraception methods.
• -Have a body mass index between 18.5 and 30 kg/m2 inclusive and weigh at least 50 kg.
• Exclusion Criteria:
• -History of any clinically important disease or disorder.
• -History of acute pancreatitis.
• -History or presence of gastrointestinal (GI) or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• -Clinically significant inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper GI tract.
• -Any clinically important illness, medical/surgical procedure, or trauma.
• -Participants who have previously received elecoglipron within the last 3 months.